



ANTABIO announces the completion of the first round of its 1 million euro seed financing

Labège, France, February 10, 2011. ANTABIO, a biopharmaceutical expert in the fight against nosocomial bacterial infections, announces the raising of 309 K€ as a first part of its 1 million euro seed financing round. The young french start-up addresses a growing global health problem, recognized as **n°1 priority by the World Health Organization**. ANTABIO develops the next generation of antibacterial drugs that treat major hospital infections by blocking the virulence of pathogenic bacteria, including the multiresistant NDM-1 strains. ANTABIO's drugs will improve current therapies and positively impact healthcare by reducing the mortality of patients and the associated costs.

The raising of 309K€ was conducted in partnership with WISEED, a crowd funding internet platform. « This transaction, which involved the constitution of a holding of shareholders in less than two months, is one of the most successful deals carried out by Wiseed to date” says enthusiastically Thierry Merquiol, CEO of Wiseed. After this first successful fundraising, ANTABIO is seeking 700K€ to finalize the 1 million euro seed financing before the end of Q2 2011. The funds will be used for the lead selection and optimization of ANTABIO's antivirulence compounds. « Partnering with Wiseed's innovative financing platform allowed us to secure the first third of our seed funding in record time » says ANTABIO's CEO and CSO Marc Lemonnier. « Given the current investment climate, this is a great support to our business and a clear vote of confidence to our products. We are very excited. ». Discussions with business angels and institutional investors towards the closing of the seed financing round are currently underway.

About ANTABIO : ANTABIO, a Labège, France-based start-up biotech company, was founded in 2009 by Marc Lemonnier and Aymeric Dugray. ANTABIO uses proprietary *in vitro* technologies and extensive bacterial disease know-how to develop the next generation of antibacterial drugs targeting major hospital infections caused by gram-negative enterobacterial pathogens, including multiresistant NDM-1 strains (www.antabio.com).

A propos de Wiseed : WISEED, a Toulouse, France-based micro investment platform with focus on innovation, offers long-term investment in young, responsible and sustainable start-up businesses. Originality: investments are made directly on the net. With a few clicks, each individual investor can choose a start-up company and become its shareholder starting with just 100 € (www.wiseed.fr).

Press contacts :

ANTABIO

M. Aymeric DUGRAY
Tel. +33 5 61 28 70 31
aymeric.dugray@antabio.com
www.antabio.com

Wiseed

M. Nicolas SERES
Tel. +33 5 31 61 62 63
n.seres@wiseed.eu
www.wiseed.fr